GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Cyclically Adjusted Price-to-FCF

MorphoSys AG (WBO:MOR) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


MorphoSys AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for MorphoSys AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Cyclically Adjusted Price-to-FCF Chart

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MorphoSys AG's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, MorphoSys AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MorphoSys AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Cyclically Adjusted Price-to-FCF falls into.



MorphoSys AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

MorphoSys AG's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, MorphoSys AG's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/123.6675*123.6675
=0.000

Current CPI (Dec. 2023) = 123.6675.

MorphoSys AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.346 99.543 -0.430
201406 -0.106 99.543 -0.132
201409 -0.386 99.823 -0.478
201412 -0.485 99.543 -0.603
201503 -0.097 99.717 -0.120
201506 -0.077 100.417 -0.095
201509 -0.282 100.417 -0.347
201512 -0.776 99.717 -0.962
201603 -0.350 100.017 -0.433
201606 -0.285 100.717 -0.350
201609 -0.481 101.017 -0.589
201612 -0.707 101.217 -0.864
201703 -0.333 101.417 -0.406
201706 -0.704 102.117 -0.853
201709 -0.550 102.717 -0.662
201712 -0.196 102.617 -0.236
201803 -0.902 102.917 -1.084
201806 -0.425 104.017 -0.505
201809 0.931 104.718 1.099
201812 -0.801 104.217 -0.950
201903 -0.747 104.217 -0.886
201906 -0.697 105.718 -0.815
201909 0.092 106.018 0.107
201912 -1.325 105.818 -1.549
202003 6.558 105.718 7.671
202006 -1.840 106.618 -2.134
202009 -1.385 105.818 -1.619
202012 -1.958 105.518 -2.295
202103 -1.314 107.518 -1.511
202106 -2.854 108.486 -3.253
202109 -5.764 109.435 -6.514
202112 -4.866 110.384 -5.452
202203 -4.246 113.968 -4.607
202206 -2.862 115.760 -3.057
202209 0.000 118.818 0.000
202212 0.000 119.345 0.000
202303 -2.097 122.402 -2.119
202306 -3.690 123.140 -3.706
202309 0.000 124.195 0.000
202312 0.000 123.668 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MorphoSys AG  (WBO:MOR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


MorphoSys AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (WBO:MOR) Business Description

Industry
Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

MorphoSys AG (WBO:MOR) Headlines

From GuruFocus

MorphoSys AG Reports First Quarter 2022 Financial Results

By Business Wire Business Wire 05-04-2022